Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>Citi Raises TP of INNOVENT BIO (01801.HK) to HKD115, Rating Buy
Recommend 4 Positive 2 Negative 0 |
||||
|
||||
|
Citi's research report said that INNOVENT BIO (01801.HK) saw its revenue jump up by 38% YoY to RMB13 billion in 2025, with a net profit of RMB834 million, turning from a loss YoY. The management reiterated the guidance for product sales to reach RMB20 billion by 2027, and noted that despite recent price adjustments and competition, sales of mazdutide is well on track. The broker raised its revenue forecasts for the company by 24% and 23% for 2026 and 2027, respectively, and increased the EPS estimates by 33% and 5% for each year. The target price was raised from HKD110 to HKD115, with a Buy rating kept. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
